An interventional study of Citrulline and Placebo in Sarcopenia and Obesity, sponsored by Université du Québec a Montréal. Completed at 1 site in Canada. Open to participants aged 60 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-05.
Sponsored by Université du Québec a Montréal · Not applicable, Interventional, and Treatment
The main objective of this study is to determine if oral supplementation of Citrulline, when combined with HIIT, can produce significant changes in body composition, muscle quality, muscle metabolism and functional capacity in older obese men and women .
The investigators hypothesize that Citrulline combined with HIIT will be more beneficial than HIIT alone which will be more beneficial than citrulline alone which will be more beneficial than placebo alone in obese elderly men and women .
Citrulline is a non-protein amino acid, isolated from watermelon, involved in the urea cycle and an arginine precursor. Participants will take 10g/d of citrulline or placebo (isocaloric).
High intensity interval training (HIIT) is a high intensity aerobic training (30 sec at 85% and up of HRmax + 1min30 at 65-70% of HRmax). they HIIT duration is 30 min/session. HIIT is recognized as beneficial to improve health in human such as Vo2max, body fat or .
Then intervention will be follow during 12 consecutive weeks.
1,206 studies on the registry are indexed under Sarcopenia; 401 are open to participants now.
This study's enrollment of 104 is above the median of 60 across 773 interventional studies indexed under Sarcopenia.
Browse Sarcopenia studies →Université du Québec a Montréal is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants that will be randomized in the first arm will be divided in either citrulline plus HIIT (CIT + HIIT or group A) or citrulline alone (CIT or group B).
Dietary Supplement: Citrulline · Other: without exercise
Participants that will be randomized in the second arm will be divided in either placebo plus HIIT (PLA + HIIT or group C) or placebo alone (PLA or group D).
Other: Placebo · Other: without exercise
Participant that will be randomized in this arm will have an exercise program (HIIT) added to their respective dietary supplement.
Dietary Supplement: Citrulline · Behavioral: Exercise
Participant that will be randomized in this arm will not have an exercise program.
Other: Placebo · Behavioral: Exercise
Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
Also known as: High intensity interval training (HIIT)
No exercise program will be assigned to participants.
Improvement in body composition and muscle quality
We will determine whether Group A improves more body composition (decreases fat mass (%), increases Leg lean mass index (kg), increases Leg muscle strength (kg)) than group C, B or D.
Time frame: 12 weeks
Exploratory aims: improvements in citrate synthase
We will determine whether Group A improves citrate synthase (CS),compared to Group C or B or D.
Time frame: 12 weeks
Exploratory aims:improvements in palmitate oxidation.
We will determine whether Group A palmitate oxidation, compared to Group C or B or D.
Time frame: 12 weeks
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Université du Québec a Montréal